CLINICAL_TRIALS
trial_result
· 2025-01-30
Clinical Trial Update: Radium-223 Dichloride Long-term Follow-up Program [Phase 4]
Summary
A Phase 4 long-term follow-up study of Radium-223 Dichloride for bone metastases has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Neoplasm Metastasis / Bone and Bones | Phase 4 | Status: COMPLETED | Results posted: 2025-01-30